Awakening the dark side: retrotransposon activation in neurodegenerative disorders

Elizabeth Ochoa Thomas,Gabbe Zuniga,Wenyan Sun,Bess Frost
DOI: https://doi.org/10.1016/j.conb.2020.01.012
IF: 7.07
2020-01-01
Current Opinion in Neurobiology
Abstract:•Elevated retrotransposon-encoded RNAs and protein products are present in several human neurodegenerative disorders.•Pathogenic forms of TDP43 lose their ability to directly bind and silence retrotransposon transcripts.•Pathogenic forms of TDP43 may contribute to retrotransposon activation by disrupting heterochromatin-mediated silencing.•Pathogenic forms of tau drive retrotransposon activation by disrupting piRNA- and heterochromatin-mediated silencing.•Use of reverse transcriptase inhibitors to suppress retrotransposition provide a potential therapeutic strategy for ALS/FTD and tauopathy.
What problem does this paper attempt to address?